The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).
FUSED IMIDAZOPYRIDINES AS REVERSIBLE INHIBITORS OF BRUTONS TYROSINE KINASE (BTK)
申请人:Merck Patent GmbH
公开号:US20220389004A1
公开(公告)日:2022-12-08
The present invention relates to fused imidazo pyridine compounds, and pharmaceutically acceptable compositions thereof, useful as BTK inhibitors.
[EN] CEREBLON BINDERS FOR THE DEGRADATION OF IKAROS<br/>[FR] LIANTS DE CÉRÉBLON POUR LA DÉGRADATION D'IKAROS
申请人:C4 THERAPEUTICS INC
公开号:WO2019191112A1
公开(公告)日:2019-10-03
The present invention provides cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway along with their use in therapeutic applications as described herein.